Mineralys Therapeutics
-
Mineralys in Radnor Sees Stock Price Explode After Hypertension Drug Test
The Radnor biopharmaceutical firm Mineralys Therapeutics saw its stock price hit new heights Monday after a positive late-stage clinical trial showed promise for its new…
-
Newtown Square’s Arrivent Plans Public Stock Offering to Fund Cancer Drug
ArriVent Biopharma in Newtown Square plans to initiate a public stock offering to raise between $137.5 million and $160 million for the development and launch…
-
ArriVent in Newtown Square raises $155M for Cancer Drug Trial
Two Delaware County life science firms are leading the way this year in equity financing. A cancer treatment drug being developed by ArriVent Biopharma in…
-
Mineralys in Radnor Raises $192M for Blood Pressure Drug
A public stock offering from Mineralys Therapeutics of Radnor netted $192 million for the company’s development of a new blood pressure drug candidate, lorundrostat, writes…
-
Mineralys in Radnor Raises Funds for new Blood Pressure Treatment
Mineralys Therapeutics, a Radnor biopharmaceutical company is hoping to raise $100 million to develop a new high blood pressure treatment, writes John George for Philadelphia…
-
Radnor Biopharma Firm Looks at Hormone Targeting to Treat Hypertension
Mineralys Therapeutics in Radnor is on its way to developing a drug that will selectively treat hypertension, writes Laura Brzyski for Philadelphia Magazine. Mineralys Therapeutics…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
